stop_circleTerminated/Withdrawn
Neoplasms
Bayer Identifier:
12672
ClinicalTrials.gov Identifier:
EudraCT Number:
EU CT Number:
Not Available
Clinical study to evaluate the maximum tolerated dose of BAY79-4620 given every 2 weeks to patients with advanced solid tumors
Trial purpose
Clinical study to determine safety, tolerability, to measure how the drug is metabolized by the body and to determine the maximum tolerated dose of BAY79-4620 given every 2 weeks to patients with advanced solid tumors
Key Participants Requirements
Sex
BothAge
18 YearsTrial summary
Enrollment Goal
2Trial Dates
April 2010 - August 2010Phase
Phase 1Could I Receive a placebo
NoProducts
BAY79-4620Accepts Healthy Volunteer
NoWhere to participate
Status | Institution | Location |
---|---|---|
Terminated | University Medical Center Utrecht | UTRECHT, 3584 CX, Netherlands |
Terminated | Erasmus Medisch Centrum | ROTTERDAM, 3075 EA, Netherlands |
Primary Outcome
- Adverse Event reportingdate_rangeTime Frame:Approximately 3 years after initiation of the trialenhanced_encryptionyesSafety Issue:
- Pharmacokinetics profile of BAY79-4620date_rangeTime Frame:End of cycle 2 (14 days per cycle)enhanced_encryptionyesSafety Issue:
Secondary Outcome
- Biomarkers evaluationdate_rangeTime Frame:Approximately 3 years after initiation of the trialenhanced_encryptionyesSafety Issue:
- Tumor response evaluationdate_rangeTime Frame:Approximately 3 years after initiation of the trialenhanced_encryptionyesSafety Issue:
- Immunogenicity evaluationdate_rangeTime Frame:Approximately 3 years after initiation of the trialenhanced_encryptionyesSafety Issue:
Trial design
Trial Type
InterventionalIntervention Type
DrugTrial Purpose
TreatmentAllocation
Non-randomizedBlinding
Open LabelAssignment
Single Group AssignmentTrial Arms
1